FY2025 Earnings Forecast for PRQR Issued By Chardan Capital

ProQR Therapeutics (NASDAQ:PRQR) – Analysts at Chardan Capital boosted their FY2025 EPS estimates for ProQR Therapeutics in a report released on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will post earnings of ($0.33) per share for the year, up from their previous estimate of ($0.34). Chardan Capital has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

Several other brokerages also recently commented on PRQR. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. HC Wainwright upped their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, March 14th. Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

ProQR Therapeutics Stock Down 2.1 %

PRQR opened at $1.40 on Thursday. The firm has a market cap of $147.30 million, a PE ratio of -4.38 and a beta of 0.24. The business has a fifty day simple moving average of $2.08 and a 200-day simple moving average of $2.59. ProQR Therapeutics has a fifty-two week low of $1.40 and a fifty-two week high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

A number of large investors have recently made changes to their positions in PRQR. Jane Street Group LLC acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth approximately $30,000. Invesco Ltd. acquired a new stake in shares of ProQR Therapeutics during the 4th quarter valued at $32,000. Alpine Global Management LLC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter valued at $39,000. Two Sigma Securities LLC purchased a new position in shares of ProQR Therapeutics during the 4th quarter valued at $40,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of ProQR Therapeutics in the fourth quarter worth $54,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).